BRAF and colorectal carcinoma: A recent retrospective study of several clinical trials demonstrated that the presence of the BRAF V600E mutation was a strong prognostic factor for overall survival (OS) in patients with stage II/III CRC, particularly for tumors with low or stable microsatellite instability (MSI-Low, MSI-Stable, or no MSI) [4].